Cargando…
Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
Targeted therapies hold promise for efficiently and accurately delivering cytotoxic drugs directly to tumor tissue to exert anticancer effects. CD47 is a membrane protein expressed in a variety of malignant tumors and hematopoietic cells, which plays a key role in immune escape and tumor progression...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133542/ https://www.ncbi.nlm.nih.gov/pubmed/35646646 http://dx.doi.org/10.3389/fonc.2022.857927 |
_version_ | 1784713590955048960 |
---|---|
author | Chiang, Zu-Chian Fang, Shubin Shen, Yang-kun Cui, Dongya Weng, Huanjiao Wang, Dawei Zhao, Yuxiang Lin, Jizhen Chen, Qi |
author_facet | Chiang, Zu-Chian Fang, Shubin Shen, Yang-kun Cui, Dongya Weng, Huanjiao Wang, Dawei Zhao, Yuxiang Lin, Jizhen Chen, Qi |
author_sort | Chiang, Zu-Chian |
collection | PubMed |
description | Targeted therapies hold promise for efficiently and accurately delivering cytotoxic drugs directly to tumor tissue to exert anticancer effects. CD47 is a membrane protein expressed in a variety of malignant tumors and hematopoietic cells, which plays a key role in immune escape and tumor progression. Although CD47 immunocheckpoint therapy has been developed in recent years, many patients cannot benefit from it because of its low efficiency. To strengthen and extend the therapeutic efficacy of anti-CD47 monoclonal antibody (mAb), we used the newly developed 7DC2 and 7DC4 mAbs as the targeting payload adaptor and VCMMAE as the toxin payload to construct novel CD47-specific immunotoxin (7DC-VCMMAE) by engineering cysteine residues. These CD47-specific ADCs have the better cell penetration, excellent DAR, similar payload distribution and good antigen-binding affinity. In vitro, 7DC-VCMMAE treatment induced death of non-small cell lung cancer (NSCLC) cell lines 95D and SPC-A1, but not A549 that express low levels of CD47 on the cell membrane. This finding suggests that 7DC-VCMMAE may possess greater therapeutic effect on NSCLC tumors expressing a high level of CD47 antigen; however, 7DC-VCMMAE treatment also promoted phagocytosis of A549 cells by macrophages. In vivo, 7DC-VCMMAE treatment had remarkable antitumor effects in a NSCLC cell line-derived xenograft (CDX) mouse model based on nonobese diabetic/severe combined immunodeficient (NOD/SCID). In summary, this study combined VCMMAE with anti-CD47 mAbs, emphasizing a novel and promising immunotherapy method for direct killing of NSCLC, which provides a valuable new way to meet the needs of the cancer therapy field. |
format | Online Article Text |
id | pubmed-9133542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91335422022-05-27 Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo Chiang, Zu-Chian Fang, Shubin Shen, Yang-kun Cui, Dongya Weng, Huanjiao Wang, Dawei Zhao, Yuxiang Lin, Jizhen Chen, Qi Front Oncol Oncology Targeted therapies hold promise for efficiently and accurately delivering cytotoxic drugs directly to tumor tissue to exert anticancer effects. CD47 is a membrane protein expressed in a variety of malignant tumors and hematopoietic cells, which plays a key role in immune escape and tumor progression. Although CD47 immunocheckpoint therapy has been developed in recent years, many patients cannot benefit from it because of its low efficiency. To strengthen and extend the therapeutic efficacy of anti-CD47 monoclonal antibody (mAb), we used the newly developed 7DC2 and 7DC4 mAbs as the targeting payload adaptor and VCMMAE as the toxin payload to construct novel CD47-specific immunotoxin (7DC-VCMMAE) by engineering cysteine residues. These CD47-specific ADCs have the better cell penetration, excellent DAR, similar payload distribution and good antigen-binding affinity. In vitro, 7DC-VCMMAE treatment induced death of non-small cell lung cancer (NSCLC) cell lines 95D and SPC-A1, but not A549 that express low levels of CD47 on the cell membrane. This finding suggests that 7DC-VCMMAE may possess greater therapeutic effect on NSCLC tumors expressing a high level of CD47 antigen; however, 7DC-VCMMAE treatment also promoted phagocytosis of A549 cells by macrophages. In vivo, 7DC-VCMMAE treatment had remarkable antitumor effects in a NSCLC cell line-derived xenograft (CDX) mouse model based on nonobese diabetic/severe combined immunodeficient (NOD/SCID). In summary, this study combined VCMMAE with anti-CD47 mAbs, emphasizing a novel and promising immunotherapy method for direct killing of NSCLC, which provides a valuable new way to meet the needs of the cancer therapy field. Frontiers Media S.A. 2022-05-12 /pmc/articles/PMC9133542/ /pubmed/35646646 http://dx.doi.org/10.3389/fonc.2022.857927 Text en Copyright © 2022 Chiang, Fang, Shen, Cui, Weng, Wang, Zhao, Lin and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chiang, Zu-Chian Fang, Shubin Shen, Yang-kun Cui, Dongya Weng, Huanjiao Wang, Dawei Zhao, Yuxiang Lin, Jizhen Chen, Qi Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo |
title | Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
|
title_full | Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
|
title_fullStr | Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
|
title_full_unstemmed | Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
|
title_short | Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
|
title_sort | development of novel cd47-specific adcs possessing high potency against non-small cell lung cancer in vitro and in vivo |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133542/ https://www.ncbi.nlm.nih.gov/pubmed/35646646 http://dx.doi.org/10.3389/fonc.2022.857927 |
work_keys_str_mv | AT chiangzuchian developmentofnovelcd47specificadcspossessinghighpotencyagainstnonsmallcelllungcancerinvitroandinvivo AT fangshubin developmentofnovelcd47specificadcspossessinghighpotencyagainstnonsmallcelllungcancerinvitroandinvivo AT shenyangkun developmentofnovelcd47specificadcspossessinghighpotencyagainstnonsmallcelllungcancerinvitroandinvivo AT cuidongya developmentofnovelcd47specificadcspossessinghighpotencyagainstnonsmallcelllungcancerinvitroandinvivo AT wenghuanjiao developmentofnovelcd47specificadcspossessinghighpotencyagainstnonsmallcelllungcancerinvitroandinvivo AT wangdawei developmentofnovelcd47specificadcspossessinghighpotencyagainstnonsmallcelllungcancerinvitroandinvivo AT zhaoyuxiang developmentofnovelcd47specificadcspossessinghighpotencyagainstnonsmallcelllungcancerinvitroandinvivo AT linjizhen developmentofnovelcd47specificadcspossessinghighpotencyagainstnonsmallcelllungcancerinvitroandinvivo AT chenqi developmentofnovelcd47specificadcspossessinghighpotencyagainstnonsmallcelllungcancerinvitroandinvivo |